Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.13 USD | -10.43% | -3.91% | -14.32% |
Apr. 17 | IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets | MT |
Apr. 17 | IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.32% | 469M | C- | ||
-2.02% | 104B | B+ | ||
+1.74% | 97.42B | B+ | ||
+0.79% | 22.2B | B | ||
-17.74% | 21.23B | B+ | ||
-11.11% | 18.33B | A- | ||
-42.83% | 16.35B | A- | ||
-16.95% | 15.06B | B | ||
+3.64% | 13.98B | C+ | ||
+33.29% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IGMS Stock
- Ratings IGM Biosciences, Inc.